Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00675233 |
Recruitment Status
:
Active, not recruiting
First Posted
: May 9, 2008
Last Update Posted
: August 31, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment for laryngeal cancer.
PURPOSE: This phase I trial is studying the side effects and best dose of laser light therapy when given together with HPPH in treating patients with dysplasia, cancer in situ, or invasive cancer of the larynx.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Head and Neck Cancer | Drug: HPPH Procedure: laser therapy | Phase 1 |
OBJECTIVES:
Primary
- To determine the maximum tolerated dose of laser light therapy using a fixed dose of HPPH in patients with dysplasia, squamous cell carcinoma in situ, or T1 squamous cell carcinoma of the larynx.
Secondary
- To determine response in patients treated with this regimen.
OUTLINE: This is a dose-escalation study of laser light therapy.
Patients undergo photodynamic therapy comprising HPPH IV over 1 hour on day 1 and laser light therapy to the tumor on day 2. Approximately 8 weeks later, patients with a partial response, no response, or a geographical miss may receive a second course of treatment.
After completion of study treatment, patients are followed at 1 week, 1 month, 3 months, and then periodically thereafter.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 29 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I Trial of Photodynamic Therapy With HPPH (2-1[Hexyloxyethyl]-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Larynx |
Actual Study Start Date : | April 25, 2008 |
Actual Primary Completion Date : | June 28, 2013 |
Estimated Study Completion Date : | June 28, 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment PDT
Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light to the tumor on day 2. At least 6 weeks later, patients achieving partial response, no response, or a geographical miss may undergo a second course of treatment.
|
Drug: HPPH
Given IV
Procedure: laser therapy
Escalating light doses with 665 nm light
|
- Toxicity [ Time Frame: 6 weeks ]
- Tumor response [ Time Frame: 3 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Biopsy-confirmed diagnosis of 1 of the following:
-
Mild to severe dysplasia of the larynx
- Dysplastic lesions > 3 mm in thickness
- Squamous cell carcinoma in situ of the larynx
-
T1 squamous cell carcinoma of the larynx
- Tumor > 3 mm in thickness
- No T2-T4 squamous cell carcinoma of the larynx
-
- Newly diagnosed or recurrent disease
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Total bilirubin > 2.0 mg/dL
- Creatinine > 2.0 mg/dL
- SGOT > 3 times upper limit of normal (ULN)
- Alkaline phosphatase > 3 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3-6 months after completion of study treatment
- No porphyria
- No hypersensitivity to porphyrin or porphyrin-like compounds
PRIOR CONCURRENT THERAPY:
- Any prior therapy allowed
- At least 4 weeks since prior and no concurrent chemotherapy or radiotherapy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00675233
United States, New York | |
Roswell Park Cancer Institute | |
Buffalo, New York, United States, 14263-0001 |
Principal Investigator: | Hassan Arshad, MD | Roswell Park Cancer Institute |
Responsible Party: | Roswell Park Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00675233 History of Changes |
Other Study ID Numbers: |
CDR0000595166 I 119207 |
First Posted: | May 9, 2008 Key Record Dates |
Last Update Posted: | August 31, 2017 |
Last Verified: | August 2017 |
Keywords provided by Roswell Park Cancer Institute:
recurrent squamous cell carcinoma of the larynx stage I squamous cell carcinoma of the larynx stage III squamous cell carcinoma of the larynx stage IV squamous cell carcinoma of the larynx stage 0 laryngeal cancer |
Additional relevant MeSH terms:
Head and Neck Neoplasms Neoplasms by Site Neoplasms |